DB
RPRX icon

Danske Bank’s Royalty Pharma RPRX Stock Holding History

Danske Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43M Buy
766,678
+178,252
+30% +$9.28M 0.09% 196
2026
Q1 		$28.2M Buy
588,426
+88,361
+18% +$3.87M 0.07% 239
2025
Q4 		$19.3M Buy
500,065
+14,400
+3% +$549K 0.04% 308
2025
Q3 		$17.1M Buy
485,665
+99,000
+26% +$3.58M 0.04% 325
2025
Q2 		$13.9M Buy
386,665
+54,547
+16% +$1.81M 0.03% 369
2025
Q1 		$10.3M Buy
332,118
+54,959
+20% +$1.74M 0.03% 400
2024
Q4 		$7.07M Buy
277,159
+21,200
+8% +$562K 0.02% 476
2024
Q3 		$7.24M Buy
255,959
+16,600
+7% +$460K 0.02% 474
2024
Q2 		$6.31M Buy
239,359
+6,500
+3% +$180K 0.02% 484
2024
Q1 		$7.07M Buy
+232,859
New +$6.86M 0.02% 501

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Danske Bank's RPRX Position: Q2 2026 in Review

Danske Bank increased its Royalty Pharma (RPRX) stake by 30% in Q2 2026, buying an estimated $9.28M and bringing the position to 766,678 shares worth $43M. The position accounts for 0.09% of the portfolio, ranked #196.

Danske Bank first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. 538 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Danske Bank held 766,678 shares of Royalty Pharma worth $43M as of Q2 2026.
  • Danske Bank bought 178,252 Royalty Pharma shares in Q2 2026, an estimated $9.28M.
  • Royalty Pharma made up 0.09% of Danske Bank's portfolio in Q2 2026, its #196 holding.
  • Danske Bank first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
  • 538 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.